Sana Biotechnology (NASDAQ:SANA) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Sana Biotechnology (NASDAQ:SANA) from a hold rating to a sell rating in a research report released on Monday morning.

A number of other equities research analysts also recently issued reports on SANA. Weiss Ratings downgraded shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Wedbush boosted their target price on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Finally, Rodman & Renshaw initiated coverage on shares of Sana Biotechnology in a research report on Monday, May 11th. They issued a “buy” rating and a $16.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $9.50.

Sana Biotechnology Stock Performance

NASDAQ:SANA opened at $3.12 on Monday. The stock has a fifty day moving average price of $3.26 and a 200-day moving average price of $3.59. The company has a market cap of $868.26 million, a price-to-earnings ratio of -3.35 and a beta of 2.13. Sana Biotechnology has a fifty-two week low of $2.61 and a fifty-two week high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. Research analysts predict that Sana Biotechnology will post -0.59 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

Several hedge funds and other institutional investors have recently made changes to their positions in SANA. AQR Capital Management LLC raised its holdings in Sana Biotechnology by 49.8% in the 1st quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock valued at $963,000 after buying an additional 190,483 shares during the last quarter. Woodline Partners LP grew its holdings in Sana Biotechnology by 13.1% during the 1st quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock worth $1,312,000 after acquiring an additional 90,515 shares during the last quarter. Franklin Resources Inc. grew its holdings in Sana Biotechnology by 86.8% during the 2nd quarter. Franklin Resources Inc. now owns 93,081 shares of the company’s stock worth $254,000 after acquiring an additional 43,247 shares during the last quarter. Rhumbline Advisers increased its position in Sana Biotechnology by 11.6% in the 2nd quarter. Rhumbline Advisers now owns 203,283 shares of the company’s stock valued at $555,000 after acquiring an additional 21,149 shares during the period. Finally, Prudential Financial Inc. acquired a new position in Sana Biotechnology in the 2nd quarter valued at approximately $50,000. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.